Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

被引：0
|
作者：
Narezkina, Anna [1 ]
Akhter, Nausheen [2 ]
Lu, Xiaoxiao [3 ]
Emond, Bruno [4 ]
Huang, Qing [3 ]
Panjabi, Sumeet [3 ]
Hilts, Annalise [4 ]
Lu, Stephanie [5 ]
Lafeuille, Helene [4 ]
Lafeuille, Marie-Helene [4 ]
Choi, Michael [6 ]
机构：
[1] Univ Calif San Diego Hlth, San Diego, CA USA
[2] Northwestern Med, Chicago, IL USA
[3] Janssen Sci Affairs LLC, Horsham, PA USA
[4] Anal Grp Inc, Montreal, PQ, Canada
[5] Anal Grp Inc, Menlo Pk, CA USA
[6] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
CLL; chronic lymphocytic leukemia/small lymphocytic lymphoma; Bruton's tyrosine kinase inhibitor; time to next treatment; treatment persistence; atrial fibrillation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-390
引用
收藏
页码：S276 / S277
页数：2
相关论文
共 50 条
  • [21] Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy
    Ayed, Ayed O.
    Parikh, Sameer A.
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2287 - 2296
  • [22] Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia
    Mato, Anthony R.
    Clasen, Suparna
    Pickens, Peter
    Gashonia, Lisa
    Rhodes, Joanna
    Svoboda, Jakub
    Hughes, Mitchell
    Nabhan, Chadi
    Ali, Naveed
    Schuster, Stephen
    Carver, Joseph
    CANCER BIOLOGY & THERAPY, 2018, 19 (01) : 1 - 2
  • [23] Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib
    De Nigris, Enrico
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    Farooqui, Mohammed Z. H.
    Gandra, Shravanthi R.
    Laliberte, Francois
    FUTURE ONCOLOGY, 2024, 20 (35) : 2723 - 2735
  • [24] Characteristics and Clinical Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Long-Term Ibrutinib Treatment in the RESONATE-2 Study
    Woyach, Jennifer A.
    Barr, Paul M.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Ahn, Inhye E.
    Ghia, Paolo
    Girardi, Vincent
    Hsu, Emily
    Jermain, Mandy
    Burger, Jan A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S278 - S278
  • [25] Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases
    Santoro, Rita Carlotta
    Falbo, Mariapia
    Levato, Luciano
    Iannaccaro, Piergiorgio
    Prejano, Simona
    BLOOD COAGULATION & FIBRINOLYSIS, 2021, 32 (02) : 159 - 161
  • [26] Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
    Woyach, Jennifer A.
    Barr, Paul M.
    Kipps, Thomas J.
    Barrientos, Jacqueline C.
    Ahn, Inhye E.
    Ghia, Paolo
    Girardi, Vincent
    Hsu, Emily
    Jermain, Mandy
    Burger, Jan A.
    CANCERS, 2023, 15 (02)
  • [27] Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies
    Mato, Anthony R.
    Samp, Jennifer C.
    Gauthier, Genevieve
    Terasawa, Emi
    Brander, Danielle M.
    CANCER BIOLOGY & THERAPY, 2018, 19 (07) : 636 - 643
  • [28] Ibrutinib Treatment and Its Impact on Circulating Immune Cells in Chronic Lymphocytic Leukemia Patients
    Morelli, Francesca
    Rapolla, Chiara Maria
    Sanna, Alessandro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S272 - S272
  • [29] Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
    Moldovianu, Ana-Maria
    Stoia, Razvan
    Vasilica, Mariana
    Ursuleac, Iulia
    Badelita, Sorina Nicoleta
    Tomescu, Andra Alina
    Preda, Oana Diana
    Bardas, Alexandru
    Cirstea, Mihaela
    Coriu, Daniel
    MEDICINA-LITHUANIA, 2023, 59 (02):
  • [30] Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT)
    Ran, Tao
    He, Jinghua
    Wu, Linda
    Panjabi, Sumeet
    Lu, Xiaoxiao
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S275 - S276
12345